Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeks
FDA submission planned by end of 2022
https://finance.yahoo.com/news/evkeeza-evinacumab-phase-3-trial-110000733.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.